These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
788 related articles for article (PubMed ID: 26994459)
1. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study. Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996 [TBL] [Abstract][Full Text] [Related]
3. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706 [TBL] [Abstract][Full Text] [Related]
4. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. Roila F; Ruggeri B; Ballatori E; Del Favero A; Tonato M J Clin Oncol; 2014 Jan; 32(2):101-6. PubMed ID: 24323030 [TBL] [Abstract][Full Text] [Related]
5. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119 [TBL] [Abstract][Full Text] [Related]
6. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Hesketh PJ; Younger J; Sanz-Altamira P; Hayden M; Bushey J; Trainor B; Krentzin M; Nowd P; Arnaoutakis K; Hesketh AM Support Care Cancer; 2009 Aug; 17(8):1065-70. PubMed ID: 19066985 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874 [TBL] [Abstract][Full Text] [Related]
8. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. Oyama K; Fushida S; Kaji M; Takeda T; Kinami S; Hirono Y; Yoshimoto K; Yabushita K; Hirosawa H; Takai Y; Nakano T; Kimura H; Yasui T; Tsuneda A; Tsukada T; Kinoshita J; Fujimura T; Ohta T J Gastroenterol; 2013 Nov; 48(11):1234-41. PubMed ID: 23338487 [TBL] [Abstract][Full Text] [Related]
9. Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer. Meattini I; Francolini G; Scotti V; De Luca Cardillo C; Cappelli S; Meacci F; Furfaro IF; Muntoni C; Scoccianti S; Detti B; Mangoni M; Nori J; Orzalesi L; Fambrini M; Bianchi S; Livi L Med Oncol; 2015 Mar; 32(3):80. PubMed ID: 25698536 [TBL] [Abstract][Full Text] [Related]
10. [Information provided by pharmacists regarding the effective timing of the coadministration of first-generation serotonin receptor antagonists and dexamethasone for chemotherapy-induced nausea and vomiting in patients receiving Doxorubicin and cyclophosphamide chemotherapy for breast cancer - the second report]. Nomura H; Kawakami H; Usui H; Suzuki S; Imoto S; Saito S Gan To Kagaku Ryoho; 2014 Sep; 41(9):1129-33. PubMed ID: 25248897 [TBL] [Abstract][Full Text] [Related]
11. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M; Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233 [TBL] [Abstract][Full Text] [Related]
12. Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. Cao J; Ouyang Q; Wang S; Ragaz J; Wang X; Teng Y; Wang B; Wang Z; Zhang J; Wang L; Wu J; Shao Z; Hu X Invest New Drugs; 2020 Apr; 38(2):507-514. PubMed ID: 32036491 [TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652 [TBL] [Abstract][Full Text] [Related]
14. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. Clemons M; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Segal R; Dent S; Gertler S; Song X; Wheatley-Price P; Dranitsaris G JAMA Oncol; 2016 Feb; 2(2):225-31. PubMed ID: 26562292 [TBL] [Abstract][Full Text] [Related]
15. Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study. Shivaprakash G; Udupa KS; Sarayu V; Thomas J; Gupta V; Pallavi LC; Pemminati S Indian J Pharmacol; 2017; 49(6):451-457. PubMed ID: 29674800 [TBL] [Abstract][Full Text] [Related]
16. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732 [TBL] [Abstract][Full Text] [Related]
17. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515 [TBL] [Abstract][Full Text] [Related]
18. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667 [TBL] [Abstract][Full Text] [Related]
20. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]